VANCOUVER, British Columbia, April 25, 2012 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 Medical Device 360 Conference on Wednesday, April 25, 2012. The conference is being held at the Millennium Gloucester Hotel, London, UK.
The IN3 Medical Device 360 Conference is hosted by Elsevier and is a medical device industry forum and networking meeting. The goal of the meeting is 'partnering medtech innovators with top investors and corporate acquirers'. Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial.
"Hospital acquired infections remain a global problem. In the United States alone, these infections drain an estimated $30-45 billion dollars per year from the healthcare system. Enox's antimicrobial technology is uniquely positioned to address this problem by utilizing nitric oxide as the mechanism of action. Nitric oxide is an ideal antimicrobial agent as it is very effective but does not have resistance issues like antibiotics do."
"The IN3 Medical Device 360 Conference will provide great exposure to European market in terms of investors and potential strategic partners," continued Rewcastle. "Our breakthrough technology has the potential to meet the needs of hospitals worldwide who are currently underserved by existing infection prevention technologies."
About Enox Biopharma, Inc.
Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to, catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.
For more information, please contact:
SOURCE Enox Biopharma, Inc.